The purpose of this trial was to determine the efficacy and safety of mXELIRI as a second-line therapy for CRC in an Asian population.
Nut intake is associated with a reduced risk of type 2 diabetes and insulin resistance.
Researchers randomly assigned 143 patients to receive cetuximab plus mFOLFOXIRI followed by cetuximab or bevacizumab maintenance.
Preclinical studies demonstrated that napabucasin — a first-in-class cancer stemness inhibitor that blocks STAT3 — may prevent self-renewal and induce cancer stem cell death.
Current screening methods have a low sensitivity for precancerous lesions and are inconvenient, leading to high rates of noncompliance.
Researchers treated 74 patients with dMMR/MSI-H mCRC with nivolumab 3 mg/kg every 2 weeks.
MEK inhibition with cobimetinib may improve the response rate with checkpoint inhibition.
Survivors assigned to an experimental arm showed an improvement in the FACT-C functional well-being sub-scale from baseline to 12 weeks.
Researchers evaluated the outcomes of 453 patients with stage I to III esophageal cancer who received definitive or preoperative chemoradiation.
After median follow-up of 2.4 and 2.9 years for women who initiated AIs and tamoxifen, respectively, no increased risk of colorectal cancer was observed among women treated with AIs.
Evidence suggests that microbiota dysbiosis occurs among patients with cancer, particularly those with cancers of the digestive tract.
While colonoscopy is considered the gold standard screening method for CRC, it can be burdensome to patients; blood tests, while less burdensome, are not necessarily as sensitive.
Epidemiologic evidence suggests that a proinflammatory diet, as measured by the dietary inflammatory index, can increase the risk of developing CRC, particularly proximal colon cancer.
For this prospective study, researchers evaluated dietary and mortality data from 1575 health care professionals with stage I to III CRC.
Researchers are evaluating the safety, tolerability, and pharmacokinetics of cobimetinib, an MEK inhibitor, in combination with atezolizumab and bevacizumab among patients with metastatic colorectal cancer.
Researchers are evaluating whether guadecitabine (SGI-110), a DNA methyltransferase inhibitor, is safe and effective in combination with cyclophosphamide and GVAX among patients with colorectal cancer.
For this follow-up analysis, several lifestyle factors including smoking status, exercise, and alcohol intake were reviewed to determine any relationship with CRC-specific survival.
Bevacizumab-awwb is a recombinant IgG1 monoclonal antibody that works by binding to vascular endothelial growth factor (VEGF) and inhibits angiogenesis.
Eligible patients had received a median of 5 prior treatment regimens, 1 of which must have included irinotecan.
About 60% of Americans are deficient in magnesium, including up to 60% of patients who are critically ill.
Evidence is mixed about the relationship between calcium intake and colorectal/prostate cancers.
SIRT plus first-line FOLFOX chemotherapy does not improve overall survival among patients with metastatic colorectal cancer.
Nivolumab demonstrated an overall response rate of 32% in all patients, including 2 patients who exhibited a complete response and 22 patients who had partial responses.
Researchers evaluated BMI data from 1,087,358 men and 707,212 women in Israel to determine any link between weight in adolescence and colon/rectal cancer incidence.
The Checkmate-142 trial enrolled 74 patients with previously treated dMMR/MSI-H colorectal cancer to receive nivolumab 3 mg/kg every 2 weeks.
FOLFOXIRI-Bev is a highly effective treatment demonstrating a high ORR, not only in managing disease progression but in yielding high rates of conversion for patients with unresectable CRC.
The panel is the first FDA-approved NGS test for colorectal cancer that can detect multiple gene mutations in a single test.
The FDA approved the supplemental Biologics License Application for panitumumab as a first-line therapy for patients with RAS wild-type metastatic colorectal cancer.
Study results presented at ASCO point to a major advance for immune therapy in advanced CEA-expressing CRC and possibly other CEA-expressing malignancies.
Consuming Korean red ginseng was reported to improve cancer-related fatigue among Korean patients with colorectal cancer (CRC) treated with FOLFOX.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma